OXFORD BIOMEDICA ENTERS INTO AGREEMENT WITH BIOGEN IDEC

Oxford BioMedica, a gene therapy company, has entered into an agreement to license its LentiVector technology to Biogen Idec for use in research activities. Under the terms of the agreement, Oxford BioMedica will receive an upfront license payment and an annual maintenance fee. Further financial details were not disclosed. LentiVector, a lentivirus-based system, is one of the most powerful technologies available for gene delivery to a wide range of cell and tissue types.

iWon (http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00043420050105&date=20050105&alias=/alias/money/cm/nw)